184 related articles for article (PubMed ID: 30157220)
1. Long-term treatment with acylated analogues of apelin-13 amide ameliorates diabetes and improves lipid profile of high-fat fed mice.
O'Harte FPM; Parthsarathy V; Hogg C; Flatt PR
PLoS One; 2018; 13(8):e0202350. PubMed ID: 30157220
[TBL] [Abstract][Full Text] [Related]
2. Beneficial long-term antidiabetic actions of N- and C-terminally modified analogues of apelin-13 in diet-induced obese diabetic mice.
Parthsarathy V; Hogg C; Flatt PR; O'Harte FPM
Diabetes Obes Metab; 2018 Feb; 20(2):319-327. PubMed ID: 28730728
[TBL] [Abstract][Full Text] [Related]
3. Chronic apelin analogue administration is more effective than established incretin therapies for alleviating metabolic dysfunction in diabetic db/db mice.
O'Harte FPM; Parthsarathy V; Flatt PR
Mol Cell Endocrinol; 2020 Mar; 504():110695. PubMed ID: 31904406
[TBL] [Abstract][Full Text] [Related]
4. Acylated apelin-13 amide analogues exhibit enzyme resistance and prolonged insulin releasing, glucose lowering and anorexic properties.
O'Harte FPM; Parthsarathy V; Hogg C; Flatt PR
Biochem Pharmacol; 2017 Dec; 146():165-173. PubMed ID: 28987595
[TBL] [Abstract][Full Text] [Related]
5. Development and characterisation of novel, enzymatically stable oxytocin analogues with beneficial antidiabetic effects in high fat fed mice.
Mohan S; McCloskey AG; McKillop AM; Flatt PR; Irwin N; Moffett RC
Biochim Biophys Acta Gen Subj; 2021 Mar; 1865(3):129811. PubMed ID: 33309687
[TBL] [Abstract][Full Text] [Related]
6. Anti-diabetic actions of esculentin-2CHa(1-30) and its stable analogues in a diet-induced model of obesity-diabetes.
Vasu S; Ojo OO; Moffett RC; Conlon JM; Flatt PR; Abdel-Wahab YHA
Amino Acids; 2017 Oct; 49(10):1705-1717. PubMed ID: 28836148
[TBL] [Abstract][Full Text] [Related]
7. Beneficial actions of a long-acting apelin analogue in diabetes are related to positive effects on islet cell turnover and transdifferentiation.
Tanday N; Irwin N; Moffett RC; Flatt PR; O'Harte FPM
Diabetes Obes Metab; 2020 Dec; 22(12):2468-2478. PubMed ID: 32844576
[TBL] [Abstract][Full Text] [Related]
8. Apelin-13 analogues show potent in vitro and in vivo insulinotropic and glucose lowering actions.
O'Harte FPM; Parthsarathy V; Hogg C; Flatt PR
Peptides; 2018 Feb; 100():219-228. PubMed ID: 29412822
[TBL] [Abstract][Full Text] [Related]
9. Comparison of independent and combined metabolic effects of chronic treatment with (pGlu-Gln)-CCK-8 and long-acting GLP-1 and GIP mimetics in high fat-fed mice.
Irwin N; Hunter K; Montgomery IA; Flatt PR
Diabetes Obes Metab; 2013 Jul; 15(7):650-9. PubMed ID: 23388064
[TBL] [Abstract][Full Text] [Related]
10. [I10W]tigerinin-1R enhances both insulin sensitivity and pancreatic beta cell function and decreases adiposity and plasma triglycerides in high-fat mice.
Srinivasan DK; Ojo OO; Owolabi BO; Conlon JM; Flatt PR; Abdel-Wahab YH
Acta Diabetol; 2016 Apr; 53(2):303-15. PubMed ID: 26138324
[TBL] [Abstract][Full Text] [Related]
11. Dogfish glucagon analogues counter hyperglycaemia and enhance both insulin secretion and action in diet-induced obese diabetic mice.
O'Harte FP; Ng MT; Lynch AM; Conlon JM; Flatt PR
Diabetes Obes Metab; 2016 Oct; 18(10):1013-24. PubMed ID: 27357054
[TBL] [Abstract][Full Text] [Related]
12. Liraglutide improves hippocampal synaptic plasticity associated with increased expression of Mash1 in ob/ob mice.
Porter WD; Flatt PR; Hölscher C; Gault VA
Int J Obes (Lond); 2013 May; 37(5):678-84. PubMed ID: 22665137
[TBL] [Abstract][Full Text] [Related]
13. Two novel glucagon receptor antagonists prove effective therapeutic agents in high-fat-fed and obese diabetic mice.
O'Harte FP; Franklin ZJ; Irwin N
Diabetes Obes Metab; 2014 Dec; 16(12):1214-22. PubMed ID: 25060150
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological characterization and antidiabetic activity of a long-acting glucagon-like peptide-1 analogue conjugated to an antithrombin III-binding pentasaccharide.
Patterson S; de Kort M; Irwin N; Moffett RC; Dokter WH; Bos ES; Miltenburg AM; Flatt PR
Diabetes Obes Metab; 2015 Aug; 17(8):760-70. PubMed ID: 25929155
[TBL] [Abstract][Full Text] [Related]
15. FGF21 decreases body weight without reducing food intake or bone mineral density in high-fat fed obese rhesus macaque monkeys.
Andersen B; Straarup EM; Heppner KM; Takahashi DL; Raffaele V; Dissen GA; Lewandowski K; Bödvarsdottir TB; Raun K; Grove KL; Kievit P
Int J Obes (Lond); 2018 Jun; 42(6):1151-1160. PubMed ID: 29892039
[TBL] [Abstract][Full Text] [Related]
16. Antagonism of gastric inhibitory polypeptide (GIP) by palmitoylation of GIP analogues with N- and C-terminal modifications improves obesity and metabolic control in high fat fed mice.
Pathak V; Gault VA; Flatt PR; Irwin N
Mol Cell Endocrinol; 2015 Feb; 401():120-9. PubMed ID: 25449420
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological Inhibition of Monoacylglycerol O-Acyltransferase 2 Improves Hyperlipidemia, Obesity, and Diabetes by Change in Intestinal Fat Utilization.
Take K; Mochida T; Maki T; Satomi Y; Hirayama M; Nakakariya M; Amano N; Adachi R; Sato K; Kitazaki T; Takekawa S
PLoS One; 2016; 11(3):e0150976. PubMed ID: 26938273
[TBL] [Abstract][Full Text] [Related]
18. Stable oxyntomodulin analogues exert positive effects on hippocampal neurogenesis and gene expression as well as improving glucose homeostasis in high fat fed mice.
Pathak NM; Pathak V; Lynch AM; Irwin N; Gault VA; Flatt PR
Mol Cell Endocrinol; 2015 Sep; 412():95-103. PubMed ID: 26048772
[TBL] [Abstract][Full Text] [Related]
19. Triphala and its constituents ameliorate visceral adiposity from a high-fat diet in mice with diet-induced obesity.
Gurjar S; Pal A; Kapur S
Altern Ther Health Med; 2012; 18(6):38-45. PubMed ID: 23251942
[TBL] [Abstract][Full Text] [Related]
20. Chemical cholecystokinin receptor activation protects against obesity-diabetes in high fat fed mice and has sustainable beneficial effects in genetic ob/ob mice.
Irwin N; Montgomery IA; Moffett RC; Flatt PR
Biochem Pharmacol; 2013 Jan; 85(1):81-91. PubMed ID: 23085436
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
